drugset / Trial / NCT04027361
Amphetamine Extended Release Tablets and Driving Performance in Subjects With Attention Deficit/Hyperactivity Disorder (ADHD)
Phase 2
Completed
41 enrolled
Tris Pharma, Inc.
Massachusetts General Hospital · collabMassachusetts Institute of Technology · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to assess the effect on driving performance of a single dose of amphetamine extended-release tablets (20 mg/tablet) compared with placebo at 45 minutes and 10 hours post-dose in young adults with ADHD.
Timeline
- Start
- 2019-10-01
- Primary completion
- 2021-10-15
- Completion
- 2021-10-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Amphetamine | Unknown | 20 mg | Oral |